Vimarsana
Biggest News Aggregation in the World

Page 3 - Multicenter Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multicenter Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multicenter Phase Today - Breaking & Trending Today

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1) - Vimarsana News

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3If...

Inhaled nitric oxide beneficial for patients with respiratory failure due to COVID-19 pneumonia - Vimarsana News

Inhaled nitric oxide beneficial for patients with respiratory failure due to COVID-19 pneumonia

Inhaled nitric oxide gas widens blood vessels in the lungs and is used to treat severe cardio-pulmonary conditions in newborns and adults. A recent multicenter international phase II clinical trial...

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks o - Vimarsana News

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks o

ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...

Burning Rock Reports Second Quarter 2023 Financial Results - Vimarsana News

Burning Rock Reports Second Quarter 2023 Financial Results

GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company...

Elicio Therapeutics Reports Second Quarter 2023 Financial - Vimarsana News

Elicio Therapeutics Reports Second Quarter 2023 Financial

ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCOAMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger...